Pomalidomide plus nivolumab for virus-related cancers
Treatments studied
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have a qualifying virus-related cancer type (for example EBV, HPV, KSHV, hepatitis B/C, or Merkel cell polyomavirus)
- Have cancer that is advanced, spread out, or has come back/progressed after standard treatments
- Have measurable disease (tumors/lesions that can be measured on scans or exams)
- Be well enough to tolerate treatment (performance status 0–2) and have blood/organ tests within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a combination of four drugs for patients with a type of lymphoma that is linked to the Epstein-Barr virus and has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.